Literature DB >> 16439542

Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.

Hoshang J Unwalla1, Hai-Tang Li, Ingrid Bahner, Ming-Jie Li, Donald Kohn, John J Rossi.   

Abstract

We demonstrate a novel approach for coexpression of a short hairpin RNA (shRNA) with an open reading frame which exploits transcriptional read-through of a minimal polyadenylation signal from a Pol II promoter. We first observed efficient inducible expression of enhanced green fluorescent protein along with an anti-rev shRNA. We took advantage of this observation to test coexpression of the transdominant negative mutant (humanized) of human immunodeficiency type 1 (HIV-1) Rev (huRevM10) along with an anti-rev shRNA via an HIV-1-inducible fusion promoter. The coexpression of the shRNA and transdominant protein resulted in potent, long-term inhibition of HIV-1 gene expression and suppression of shRNA-resistant mutants. This dual expression system has broad-based potential for other shRNA applications, such as cases where simultaneous knockdown of mutant and wild-type transcripts must be accompanied by replacement of the wild-type protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439542      PMCID: PMC1367144          DOI: 10.1128/JVI.80.4.1863-1873.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs.

Authors:  Rui Yi; Yi Qin; Ian G Macara; Bryan R Cullen
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

2.  Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.

Authors:  M H Malim; D F McCarn; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Varied poly(A) site efficiency in the adenovirus major late transcription unit.

Authors:  J C Prescott; E Falck-Pedersen
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

4.  Sequences regulating temporal poly(A) site switching in the adenovirus major late transcription unit.

Authors:  J D DeZazzo; E Falck-Pedersen; M J Imperiale
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

5.  Sequences upstream of AAUAAA influence poly(A) site selection in a complex transcription unit.

Authors:  J D DeZazzo; M J Imperiale
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

Review 6.  Complex transcriptional units: diversity in gene expression by alternative RNA processing.

Authors:  S E Leff; M G Rosenfeld; R M Evans
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

7.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

8.  Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.

Authors:  D Bevec; M Dobrovnik; J Hauber; E Böhnlein
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition.

Authors:  Atze T Das; Thijn R Brummelkamp; Ellen M Westerhout; Monique Vink; Mandy Madiredjo; René Bernards; Ben Berkhout
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.

Authors:  Ellen M Westerhout; Marcel Ooms; Monique Vink; Atze T Das; Ben Berkhout
Journal:  Nucleic Acids Res       Date:  2005-02-01       Impact factor: 16.971

View more
  25 in total

1.  Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells.

Authors:  Yiqi Seow; Christopher R Sibley; Matthew J A Wood
Journal:  RNA       Date:  2012-05-30       Impact factor: 4.942

2.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  Tat-regulated expression of RNA interference: triggers for the treatment of HIV infection.

Authors:  Hoshang Unwalla; John J Rossi
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

Review 4.  Selection of RNAi-based inhibitors for anti-HIV gene therapy.

Authors:  Stefanie A Knoepfel; Mireille Centlivre; Ying Poi Liu; Fatima Boutimah; Ben Berkhout
Journal:  World J Virol       Date:  2012-06-12

5.  Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Authors:  Touraj Farazmandfar; Mohammad Reza Haghshenas; Majid Shahbazi
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

Review 6.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

7.  A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle.

Authors:  Hoshang J Unwalla; John J Rossi
Journal:  Virol J       Date:  2010-02-10       Impact factor: 4.099

8.  Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression.

Authors:  Xue-Ming Xu; Min-Hyuk Yoo; Bradley A Carlson; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

9.  Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference.

Authors:  Karin Jasmijn von Eije; Olivier ter Brake; Ben Berkhout
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

Review 10.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.